J&J’s Bold Restructuring Revealed | Durham News

Johnson & Johnson is executing a bold corporate reset—spinning off its world-leading orthopaedics division to focus laser-sharp on high-growth oncology, immunology, and neuroscience. With record $100B in revenue and a 64-year dividend streak, the company’s strategic pivot is already paying off: oncology sales are projected to hit $50B by 2030, fueled by blockbuster cancer drugs. A major legal hurdle around talc lawsuits is also being resolved, removing investor uncertainty. All eyes turn December 8th for their Enterprise Business Review, where J&J will unveil its long-term growth blueprint—and prove whether this transformation is the future or just another gamble. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/322cd9860ce53ebc